leisure time -WSS

leisure time

author：fashion 2025-10-01 17:21:38 - browse：74678

A pharmacist hands a box of Wegovy — first opinion coverage from STAT — Bloomberg photo by George Frey

LONDON — Novo Nordisk said Wednesday that it had started to increase the availability of its blockbuster obesity drug Wegovy for new patients in the United States, after massive demand and a supply crunch had led it to limit doses last May.

The announcement that Novo was making more of its lower-dose starter product available as of this month came as the company reported its 2023 earnings, with sales up by 36% and operating profit up 44% at constant exchange rates, driven by enormous sales of Wegovy and Ozempic, the company’s sister drug for diabetes. The company also projected double-digit growth in sales and operating profit for 2024.

“I am pleased to state that we are now enabling more new U.S. patients to initiate treatment by more than doubling the amount of lower-dose strength Wegovy compared to previous months,” Novo CEO Lars Fruergaard Jørgensen said on a call with reporters.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Hepatitis C has a cure — but many Americans still lack access to it
Next article： AI can’t replace a physician’s gut feeling

focus

WSS

Supreme Court strikes down Biden student loan forgiveness program

Brazil's Jair Bolsonaro is barred from running for office until 2030

Prince Harry seeks over $550,000 in phone hacking lawsuit against British tabloid publisher

Why hospitals are withdrawing from US News rankings

In early work, researchers turn to CRISPR to treat Alzheimer's

What Wagner Group's armed rebellion could mean for Russia's endgame in Ukraine

focus

leisure time

explore

State Dept. review finds Biden bears some blame for Afghanistan failures

At Orexo, a ‘turning point’ for everything but digital health

Biden outlines 'new path' to provide student loan relief after Supreme Court rejection

Belarusian journalist sentenced to 4 years in prison as crackdown continues

Trump demands the U.S. pay no more for drugs than other countries … again

Medicare has a new plan to address drug shortages

How one medical school became remarkably diverse

Synthetic human embryos? Researchers say term is overblown

How to save PrEP access — and even expand it

The strange history of BMI, the body mass index

focus

Here's how to stay safe from wildfire smoke amid reduced air quality

Federal board approves $12.7 billion budget for Puerto Rico as island shakes off bankruptcy

Medical experts exlpore how to eliminate bias in clinical algorithms

As digital health tech proliferates, a new institute aims to cut through hype

Thousands protest in Iraq for a second day over burning of Quran in Sweden

Eating disorder hotline's move to chatbot carried cost for volunteers

focus

leisure time

explore

focus